Juvaris Gets Strategic Funding

Pleasanton-based Juvaris Therapeutics, which is developing adjuvanted vaccines for improving the effectiveness of influenza vaccination, said today that it has had a second close of its Series B funding worth up to $25M. The new funding came from an undisclosed corporate investor. The firm has previously raised funding from SV Life Sciences and Kleiner Perkins Caufield & Byers. The company said the new funding will go towards advancing its platform. More information »